Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch

This article was originally published in The Tan Sheet

Executive Summary

Despite concerns raised by the Nonprescription Drug Advisory Committee in November, FDA approves Merck’s overactive bladder drug Oxytrol for Women for OTC use. The company plans a launch in the fall.

Advertisement

Related Content

Top OTC Stories 2013: Switch, Consumer Business Divestment Plans
Top OTC Stories 2013: Switch, Consumer Business Divestment Plans
Oxytrol Switch Should Hinge On Symptom ID, Not Diagnosis – Merck Consultant

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel